Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used to host the headquarters for its 2022-acquired Global Blood Therapeutics.

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

Pfizer's recent phase 2 win was encouraging, but not yet a slam dunk. The company could make significant clinical and regulatory progress in the next few years. On March 17, Pfizer announced that an ...

Pfizer plans to shutter its South San Francisco research offices on April 30, ending its short tenure in the city. Pfizer planted its flag in South San Francisco in 2022 when it acquired Global Blood ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An illustration photo shows a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine from Skippack ...

When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory approval for a new vaccine candidate, CNBC reported. In April 2020, Pfizer and ...

Pfizer (PFE) is preparing to shut a research site and an office location in South San Francisco at the end of April, signaling a notable pullback from the Bay Area’s flagship biotech space, the San ...

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a ...

Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of ...

This week, Pfizer and French vaccine company, Valneva, released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective. While ...

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.